DDInter469 DDInter899
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Dalfopristin {u} (Compound) binds {v} (Gene) CYP3A4
Dalfopristin {u} (Compound) is included by {v} (Pharmacologic Class) Streptogramins
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sibutramine
Dalfopristin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fedratinib
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mycophenolic acid
Dalfopristin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Dalfopristin {u} may lead to a major life threatening interaction when taken with {v} Encorafenib
Dalfopristin {u} may lead to a major life threatening interaction when taken with {v} Tamoxifen
Dalfopristin (Compound) binds CYP3A4 (Gene)
Dalfopristin (Compound) is included by Streptogramins (Pharmacologic Class)
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Dalfopristin may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid
Dalfopristin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Dalfopristin may lead to a major life threatening interaction when taken with Encorafenib
Dalfopristin may lead to a major life threatening interaction when taken with Tamoxifen